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Galectin-1 (Gal-1), a glycan-binding protein with broad antiinflamma-
tory activities, functions as a proresolving mediator in autoimmune
and chronic inflammatory disorders. However, its role in allergic
airway inflammation has not yet been elucidated. We evaluated the
effects of Gal-1 on eosinophil function and its role in a mouse model
of allergic asthma. Allergen exposure resulted in airway recruitment
of Gal-1–expressing inflammatory cells, including eosinophils, as well
as increased Gal-1 in extracellular spaces in the lungs. In vitro, extra-
cellular Gal-1 exerted divergent effects on eosinophils that were
N-glycan– and dose-dependent. At concentrations ≤0.25 μM, Gal-1
increased eosinophil adhesion to vascular cell adhesion molecule-1,
caused redistribution of integrin CD49d to the periphery and cell
clustering, but inhibited ERK(1/2) activation and eotaxin-1–induced
migration. Exposure to concentrations ≥1 μM resulted in ERK(1/2)-
dependent apoptosis and disruption of the F-actin cytoskeleton. At
lower concentrations, Gal-1 did not alter expression of adhesion mol-
ecules (CD49d, CD18, CD11a, CD11b, L-selectin) or of the chemokine
receptor CCR3, but decreased CD49d and CCR3 was observed in
eosinophils treated with higher concentrations of this lectin. In vivo,
allergen-challenged Gal-1–deficient mice exhibited increased recruit-
ment of eosinophils and CD3+ T lymphocytes in the airways as well as
elevated peripheral blood and bone marrow eosinophils relative to
corresponding WT mice. Further, these mice had an increased pro-
pensity to develop airway hyperresponsiveness and displayed signif-
icantly elevated levels of TNF-α in lung tissue. This study suggests that
Gal-1 can limit eosinophil recruitment to allergic airways and sup-
presses airway inflammation by inhibiting cell migration and promot-
ing eosinophil apoptosis.
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Allergic asthma is an inflammatory disease of the airways thatis associated with increased pulmonary recruitment of in-
flammatory cells, especially eosinophils, elevated levels of Th2
cytokines, proinflammatory chemokines, and growth factors that
together contribute to the overall pathogenesis of the disease
including the development of bronchoconstriction and airway
hyperresponsiveness (AHR) (1). This disease is to a large extent
driven by activation of Th2 cells and airway eosinophilia. Fur-
ther, decreased number and/or function of regulatory T cells
(Tregs) is also thought to contribute to atopic allergic disease
and asthma in patients (2). Although various therapeutic ap-
proaches targeting T cells or cytokines and chemokines released
by these cells have been developed, positive outcomes are either
limited to small subpopulations (3) or vary significantly among
patient groups, thus warranting the need for identification of
novel or alternate therapeutic approaches.
Galectin-1 (Gal-1) is a glycan-binding protein that binds to
N-acetyl-lactosamine (Gal-β1-3/4-N-acetyl-D-glucosamine or LacNAc)
residues of complex N- and O-glycans on cell-surface glyco-
conjugates (4). Gal-1 has wide distribution in adult tissue including
the lung, and is expressed by various cell types such as poly-
morphonuclear cells (PMNs), macrophages, dendritic cells
(DCs), activated T cells, stromal cells, endothelial cells, and
epithelial cells (5, 6). At a cellular level, Gal-1 may act either
intracellularly or extracellularly, and is profoundly involved in
resolving acute and chronic inflammation by affecting processes
such as immune cell adhesion, migration, activation, signaling,
proliferation, differentiation, and apoptosis (5, 7). Increasing evi-
dence from multiple chronic inflammatory disease models sup-
ports the critical antiinflammatory role of exogenous and
endogenous Gal-1 in limiting or resolving inflammation (6). Addi-
tionally, Gal-1 showed proresolving effects in models of acute in-
flammation where neutrophil recruitment (8) and extravasation (9)
as well as mast cell degranulation were suppressed (9). The im-
munosuppressive role of Gal-1 was further supported by studies
with Tregs where cells from Gal-1 null mice exhibited reduced
regulatory activity (10). More recent studies emphasized the
immunosuppressive effect of Gal-1 in macrophages and cells of
the microglia compartment, which showed a shift toward an M2
phenotype and reduced secretion of proinflammatory cytokines
upon exposure to this lectin (11).
Given the critical antiinflammatory and proresolving function
of Gal-1 in innate and adaptive immune compartments and its broad
expression in lung tissue, we hypothesized that this endogenous
lectin might regulate eosinophil function and airway inflammation.
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Clinical studies have shown that sputum leukocytes (largely
macrophages) from asthmatic patients have decreased intracel-
lular Gal-1 relative to cells from healthy subjects, suggesting that
decreased Gal-1 expression might favor exacerbation of asthma
(12). In the present study, we examined the regulated expres-
sion and biological relevance of endogenous and exogenous/
extracellular Gal-1 in eosinophil function in vitro and in a model
of allergic asthma.
Results
Expression of Gal-1 Is Induced in Allergic Lungs. We examined the
expression of Gal-1 in the lungs during allergic inflammation in a
mouse model. In control mice, baseline Gal-1 expression was
observed mostly in airway epithelial cells, smooth muscle cells,
and endothelial cells by immunohistochemistry (IHC; Fig. 1A,
Upper, Left and Middle). Acute or chronic ovalbumin (OVA)
exposure resulted in increased Gal-1 expression in the lungs that
was largely observed in the recruited inflammatory cells in ad-
dition to expression in airway epithelial cells, smooth muscle
cells, and endothelial cells (Fig. 1A, Lower, Left and Middle).
Further, increased Gal-1 expression was detected in extracellular
spaces after allergen exposure (Fig. 1A, Right, Upper and Lower).
Dual immunofluorescence (IF) staining of lung sections from
allergen-challenged mice for Gal-1 and eosinophil peroxidase
(EPX), an eosinophil-specific marker, revealed several cells that
stained positively for Gal-1 (red) and EPX (green) in addition to
cells that were positive for Gal-1 but negative for EPX (Fig. 1B,
Lower). These findings indicate that eosinophils, the major in-
flammatory cells recruited to allergic airways, express Gal-1.
Total lung Gal-1 expression was significantly higher in acute
OVA-challenged mice compared with saline-exposed controls at
the level of mRNA and protein (Fig. 1 C and D). Soluble Gal-1
was not detectable in the bronchoalveolar lavage fluid (BALF)
of OVA-challenged mice, whereas Gal-3 was easily detected in
these samples (Fig. S1A). Exposure to other allergens such as
Alternaria alternata extract (Fig. S1B) or cockroach antigen
(CRA; Fig. S1 C and D) also resulted in increased Gal-1 expres-
sion in the lungs of mice similar to OVA. Thus, allergic airway
inflammation irrespective of the nature of allergen exposure
results in up-regulated expression of Gal-1.
Gal-1 Binds to Eosinophils in a Carbohydrate-Dependent Manner.We
examined Gal-1 expression at the cellular level using bone mar-
row (BM)-derived murine eosinophils and identified a protein
band of ∼14.5 kDa corresponding to Gal-1 in its monomeric
form (13) (Fig. 2A). Interestingly, flow cytometry studies revealed
that Gal-1 expression by eosinophils (nonactivated) was detectable
only when cells were permeabilized (Fig. 2B, Right), with no
positive staining for this lectin under nonpermeabilized condi-
tions (Fig. 2B, Left). This suggests that in resting eosinophils,
Gal-1 is expressed intracellularly but is undetectable on the cell
surface. Further, IF staining of permeabilized eosinophils in-
dicated that Gal-1 was predominantly expressed in the cytosolic
compartment (Fig. 2C).
Because allergen exposure results in increased Gal-1 expres-
sion in extracellular spaces (Fig. 1A), it is likely that eosinophils
recruited to the airways are exposed to Gal-1 extracellularly. We
found that soluble recombinant Gal-1 (rGal-1) binds to the
surface of eosinophils in a dose-dependent fashion (Fig. 2D,
Left). Exposure to rGal-1 in the presence of increasing concen-
trations of lactose, a specific disaccharide inhibitor, but not
maltose (negative control), inhibited Gal-1 binding to the cell
surface, indicating that Gal-1 binds to surface ligands on eosin-
ophils in a carbohydrate-dependent manner (Fig. 2D, Right).
Intracellular (protein and mRNA) and cell-surface expression of
Gal-1 were not altered in eosinophils after stimulation/activation
with TNF-α, eotaxin-1 (CCL11), or stem cell factor-1 (SCF-1) (Fig.
S2 A and B). Further, Western blot analysis of culture supernatant
concentrates (∼10-fold) from these activated eosinophils was neg-
ative for Gal-1 immunoreactivity, suggesting that Gal-1 may not
be secreted in detectable levels by eosinophils.
Eosinophils Express the Repertoire of Cell-Surface Glycans Required
for Gal-1 Binding and Function.Gal-1 is well-known for its ability to
recognize complex N- and O-glycans containing unmodified or
terminally modified (α2,3-sialylated) LacNAc residues (5). To
identify Gal-1–binding carbohydrate partners on eosinophils, we
analyzed the glycophenotype of these cells using an array of la-
beled plant lectins with known carbohydrate-binding specificities
by flow cytometry. Murine eosinophils express complex N-gly-
cans [β1-6 branched N-linked carbohydrates, based on Phaseolus
vulgaris leucoagglutinin (PHA)-L reactivity] as well as O-glycans
[asialo core-1 O-glycans bearing terminal galactose residues
(Galβ1-3GalNAcαSer-Thr), based on peanut agglutinin (PNA)
reactivity] (Fig. 3A). Based on staining intensity, eosinophils
expressed predominantly glycans containing poly-LacNAc
[Lycopersicon esculentum (tomato) lectin (TL) reactivity] and to
a lesser extent glycans containing α2,3-linked sialic acid residues
[Maackia amurensis lectin-II (MAL-II) reactivity] and α2,6-linked
sialic acid residues [Sambucus nigra lectin (SNA) reactivity], thus
demonstrating the presence of many potential Gal-1–binding
partners on their cell surface. When pretreated with these lectins,
Fig. 1. Expression of Gal-1 is induced in allergic
lungs. (A) Gal-1 expression in lungs of mice exposed
to allergen challenge (or saline alone as control) by
IHC. Gal-1 expression in airway epithelial cells (black
arrowheads), endothelial cells (red arrow), smooth
muscle cells (red arrowheads), inflammatory cells
(black arrows), and extracellular spaces (blue arrow)
is shown. [Scale bars, 50 μm (Left) and 10 μm (Right).]
(B) Lung sections from OVA-exposed mice dual-
stained with antibodies against Gal-1 (red) and
eosinophil-specific mouse anti-human EPX (green)
(Bottom) or rabbit and mouse IgG as controls (Top).
(Scale bar, 10 μm.) (C) Gal-1 mRNA (Left) and protein
(Right) expression in lungs of OVA (acute)-chal-
lenged or saline-exposed mice. (D) Gal-1 expression
in lung tissue of three representative mice (M1–M3)
for each group. Data are representative of n = 6 mice
per group in A and n = 3 mice per group in B. Com-
bined data (mean ± SEM) of n = 5–7 mice per group
are shown in C. *P < 0.05 (Left) and *P < 0.01 (Right)
in C for control versus allergen-challenged group.
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only TL showed partial, albeit significant, reduction in binding of
rGal-1 to the cell surface (Fig. 3B), substantiating the in-
volvement of LacNAc residues in Gal-1 binding. Studies with
eosinophils where O-linked glycosylation was specifically inhibited
using benzyl-α-GalNAc (BG), an inhibitor of O-linked oligo-
saccharide chain elongation, demonstrated significantly in-
creased Gal-1 binding (Fig. 3C). This suggests that, at least in the
case of eosinophils, O-glycosylation may mask Gal-1 effects. How-
ever, binding of Gal-1 to eosinophils required complex branched
N-glycans. Gal-1 binding to BM-derived eosinophils from mice
deficient in UDP-N-acetylglucosamine:α-6-D-mannoside β1,6
N-acetylglucosaminyltransferase V (Mgat5, Mgat5−/−), which
lack tetraantennary N-glycans, was substantially lower than
binding to their WT counterparts (Fig. 3D). These findings in-
dicate that Gal-1 binding to eosinophils is mediated in part via
interaction with complex N-linked glycans and does not require
the presence of O-glycans.
Exogenous Gal-1 Induces Apoptosis in Eosinophils. Given the role of
extracellular Gal-1 in promoting apoptosis of activated as well as
fully differentiated T cells (14, 15) and modulating phosphati-
dylserine exposure (without engaging the full apoptotic program)
in PMNs (16), we examined the direct effects of rGal-1 on eosinophil
survival. Significant loss of cell viability (based on trypan blue
dye staining) was observed when eosinophils were exposed
to rGal-1 at concentrations of 1.0 μM or higher for 15 min,
whereas no effect was noted at lower concentrations (Fig. 4A).
Gal-1 induced phosphatidylserine exposure in eosinophils, an early
apoptotic event, in a dose-dependent manner (Fig. 4B) at time
points as early as 5 min at a concentration of 5 μM (Fig. 4C), as
shown by annexin V staining. Under these conditions, rGal-1 also
modulated later events in the apoptosis cascade, as shown by
TUNEL assay. A substantial number of rGal-1–treated eosino-
phils were positive for TUNEL staining similar to cells treated
with staurosporine, a well-known apoptotic stimulus, whereas
control cells [PBS-treated (for Gal-1) and DMSO-treated (for
staurosporine)] were negative for TUNEL staining (Fig. 4D).
Treatment with rGal-1 also resulted in clustering of cells relative
to control cells or cells treated with staurosporine, an effect
commonly observed in the presence of exogenous Gal-1 (17).
Further, rGal-1 exerted a similar effect on peripheral blood
eosinophils. Treatment of peripheral blood leukocytes from
allergen-challenged mice with 1.0 μM rGal-1 resulted in an ap-
proximately threefold increase in the number of Siglec-F–positive
cells (eosinophils) that stained positive for annexin V (Fig. 4E).
The glycan-binding requisite for Gal-1–induced eosinophil apo-
ptosis was established by studies wherein treatment of cells with
rGal-1 in the presence of lactose but not maltose completely
inhibited apoptosis (Fig. 4F). In addition, a substantial number
of eosinophils exposed to rGal-1 at 5 μM were found to undergo
shape change, potentially cell shrinkage, based on the decrease
in mean forward scatter (FSC) detected compared with un-
treated cells (Fig. 4G, Left). This decrease in FSC was inhibited
by lactose but not maltose (Fig. 4G, Right).
To examine whether Gal-1–induced eosinophil apoptosis is
mediated via cell-surface elongated O-glycans and/or complex
branched N-glycans, cells treated with BG as described earlier or
Mgat5−/− eosinophils were exposed to rGal-1. rGal-1–induced cell
Fig. 2. Murine eosinophils express Gal-1 intracellu-
larly and bind to Gal-1 on the cell surface. (A) Ex-
pression of Gal-1 in lysates of BM eosinophils from
two representative mice (M1 and M2) byWestern blot
analysis. (B) Expression of Gal-1 in BM-derived eosin-
ophils by flow cytometry. Note that Gal-1 expression is
detected only in permeabilized cells. (C) IF staining of
permeabilized eosinophils with anti–Gal-1 (Bottom) or
rabbit IgG (Top). (Scale bar, 10 μm.) (D) Dose-dependent
Gal-1 binding to nonpermeabilized eosinophils in
the absence (Left) or presence (Right) of increasing
concentrations of lactose (Lac) or maltose (Mal).
Data are representative of three independent ex-
periments with eosinophils from different mice.
Fig. 3. Gal-1 binding to eosinophil-expressed glycans. (A) Glycophenotype
analysis of BM eosinophils. Cells were incubated with specific plant lectins
followed by streptavidin-conjugated DyLight 488 and then analyzed by flow
cytometry. (B) Gal-1 binding to eosinophils pretreated with TL or vehicle
(PBS) examined by flow cytometry with Gal-1 antibody. gMFI, geometric
mean fluorescence intensity. (C) Role of O-glycans in Gal-1 binding. Eosin-
ophils cultured in medium containing BG (2 mM) or vehicle (DMSO) were
treated with rGal-1 and examined for Gal-1 binding. (D) Requirement of
complex branched N-glycans for Gal-1 binding. WT andMgat5−/− eosinophils
(nonpermeabilized) were treated with rGal-1 and examined for Gal-1
binding. Data in A and D are representative of three independent experi-
ments with eosinophils from different mice. Combined data (mean ± SEM)
of four experiments are shown in B and C. *P < 0.01 in B and *P < 0.03 in C
versus vehicle-treated cells.
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death was higher in BG-treated cells compared with corresponding
vehicle-treated cells (Fig. 5A), confirming the fact that O-glycans
may mask Gal-1 effects. On the other hand,Mgat5−/− eosinophils
showed reduced Gal-1–induced apoptosis relative to WT eosin-
ophils (Fig. 5B), suggesting that Gal-1–induced eosinophil apoptosis
is partly mediated by complex β1-6 branched N-glycans. Exposure
of cells to rGal-1 at proapoptotic concentrations (1–5 μM) resulted
in a marked increase in phosphorylated ERK(1/2) relative to
untreated cells (Fig. 5C, Left and Right). Surprisingly, this effect
was associated with a significant decrease in the levels of total
ERK(1/2). Interestingly, pretreatment of eosinophils with MG132, a
proteasome inhibitor that inhibits degradation of ubiquitin-tagged
proteins, before exposure to rGal-1 prevented the reduction in total
ERK levels (Fig. 5D, Left and Right). These studies suggest that
rGal-1–induced apoptosis is mediated via a rapid and strong
activation of ERK(1/2) and is associated with degradation of
ERK(1/2) by the proteasome.
To further investigate the signaling pathway(s) implicated in
this effect, eosinophils were pretreated with inhibitors of signaling
molecules such as Syk, Rho-associated protein kinase-1 (ROCK1),
phosphoinositide 3-kinase (PI3K), mitogen-activated protein ki-
nase kinase (MEK), and caspases before incubation with rGal-1
and then analyzed for annexin V binding. Significant dose-de-
pendent inhibition of annexin V binding was noted only with the
MEK inhibitor U0126, not with inhibitors of Syk, ROCK1, or
PI3K (Fig. 5E). Because Gal-1–induced apoptosis in T cells is
modulated via activation of caspases (18), we examined the in-
volvement of caspases in Gal-1–induced apoptosis of eosinophils.
Pretreatment with the pan-caspase inhibitor Z-VAD-FMK up to
100 μM did not inhibit Gal-1–induced eosinophil apoptosis.
In contrast, this inhibitor substantially reduced staurosporine-
induced apoptosis, which is known to be caspase-mediated at this
concentration (Fig. 5F). These studies suggest that Gal-1–induced
apoptosis of eosinophils involves activation of the ERK(1/2)
signaling pathway and may be independent of caspase activation.
This is further supported by the lack of caspase-3 activation in
rGal-1–treated eosinophils. Unlike staurosporine, rGal-1 treatment
did not result in an increase in expression of cleaved caspase-3
(∼17 kDa) by Western blot analysis (Fig. 5G).
Exposure to Gal-1 Differentially Controls Eosinophil Adhesion and
Migration. We examined the effect of rGal-1 on the ability of
eosinophils to adhere to vascular cell adhesion molecule-1 (VCAM-1),
which supports eosinophil trafficking and recruitment to sites of
inflammation. Because rGal-1 induces apoptosis of eosinophils at
concentrations of 1.0 μM or higher, these studies were carried out
at lower doses of rGal-1. Cells exposed to lower concentrations
of rGal-1 exhibited increased adhesion to recombinant murine
VCAM-1 in a dose-dependent manner compared with untreated
cells under static conditions (Fig. 6A). However, despite the in-
creased adhesion, eosinophils treated with rGal-1 at these con-
centrations demonstrated significantly reduced migration toward
eotaxin-1 in in vitro chemotaxis assays (Fig. 6B), an effect that was
accompanied by inhibition of ERK(1/2) activation (Fig. 6C). This
is in contrast to the increased activation of ERK(1/2) observed
in eosinophils exposed to higher concentrations of rGal-1 in the
apoptosis studies described above.
We investigated whether treatment with Gal-1 alters the ex-
pression of cell-surface adhesion molecules that mediate eosin-
ophil adhesion and migration by flow cytometry. Exposure to
Gal-1 up to 0.25 μΜ did not appear to alter the level of ex-
pression of α4 (CD49d), β2-, αL-, or αM-integrins, L-selectin, or
the eotaxin receptor CCR3 on the cell surface (Fig. S3A). How-
ever, confocal microscopy following dual IF staining with anti-
bodies against α4 and Gal-1 indicated that relative to the more
dispersed α4 expression noted in untreated cells, treatment of
eosinophils with rGal-1 not only induced cell clustering but also
resulted in redistribution of α4 to the periphery/edge of individual
cells in the cluster, where strong Gal-1 expression was also ob-
served (Fig. 6D). Further, several cells exhibited colocalization of
α4-integrin and Gal-1. This Gal-1–mediated effect was inhibited
when cells were treated with lactose but not maltose. The ability of
Gal-1 to interact with α4-integrins was investigated using human
α4-transfected Chinese hamster ovary (α4β1-CHO-K1) cells that
express functional α4β1 relative to control CHO-K1 cells that do
not (Fig. S3B). α4-CHO-K1 and control CHO-K1 cells were found
to inherently express Gal-1 on their cell surface. However, in-
creased cell-surface binding of exogenous rGal-1 to α4-CHO-K1
cells was noted relative to nontransfected cells (Fig. S3C, Upper).
Fig. 4. Exogenous Gal-1 induces eosinophil apo-
ptosis. (A) Effect of rGal-1 on the absolute number of
live cells by trypan blue dye exclusion at the in-
dicated doses. (B and C) Flow cytometric analysis
after annexin V staining of eosinophils exposed to
different concentrations of rGal-1 and eosinophils
treated with 5.0 μM rGal-1 for different durations of
time, respectively. (D) Analysis of cell death in eosin-
ophils (stained brown) after rGal-1 or staurosporine
(positive control) treatment by TUNEL assay. (Scale bar,
50 μM.) (E) Annexin V staining of peripheral blood leu-
kocytes exposed to rGal-1. Annexin V positivity of cells
gated for Siglec-F–positive staining (eosinophils) is
shown. (F) Inhibition of Gal-1–induced apoptosis by
lactose but not maltose (negative control). (G) Effect
of rGal-1 on eosinophil shape change. FSC versus side
scatter dot plots are shown. (G, Left) Dose-dependent
cell shrinkage in Gal-1–treated eosinophils. (G, Right)
Blockade of this effect by lactose but not maltose.
Combined data (mean ± SEM) of three independent
experiments with cells from n = 3–7 mice are shown in
A and E. Data shown in B–D, F, and G are representa-
tive of two or three experiments with eosinophils from
different mice. *P < 0.01 in A and E for comparison
with PBS-treated cells.
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Further, this increased binding of exogenous rGal-1 to α4-CHO-
K1 was glycan-dependent and inhibited by lactose (Fig. S3C,
Lower). Because Gal-1 exerts differing effects on eosinophils
depending on the concentration (alteration of adhesion and mi-
gration at lower concentrations versus apoptosis at higher con-
centrations), we next examined the effect of Gal-1 at a higher
concentration (1.0 μM, proapoptotic) on cell-surface expression
of these receptors. Interestingly, only expression of α4 and CCR3
was partially reduced at this concentration (Fig. 6E). Finally,
because Gal-1 alters eosinophil motility and survival, its effect on
the actin cytoskeleton was evaluated based on phalloidin staining
(indicative of actin polymerization). Gal-1 at lower concentra-
tions (0.25 μM) had no effect, whereas apoptosis-inducing con-
centrations resulted in a marked reduction in phalloidin binding
relative to untreated cells by flow cytometry (Fig. 6F). Further,
confocal microscopy revealed distinct phalloidin binding predomi-
nantly at the cell periphery/margin of control cells (Fig. 6G, Left),
whereas Gal-1 treatment at proapoptotic concentrations caused
disruption of this organized actin cytoskeleton in many cells, with an
overall decrease in phalloidin binding (Fig. 6G, Right).
Gal-1 Deficiency Results in Increased Allergen-Induced Airway
Inflammation. To understand the pathophysiological relevance of
Gal-1 in allergic airway inflammation, WT and Gal-1–deficient
(lectin galactoside-binding soluble 1 [Lgals1−/−]) mice were sensi-
tized and challenged with OVA. OVA challenge induced a marked
influx of inflammatory leukocytes in the BALF of WT and Lgals1−/−
mice. However, the total number of inflammatory cells and spe-
cifically of eosinophils and lymphocytes was significantly higher in
the BALF of OVA-challenged Lgals1−/− mice (Fig. 7 A and B).
Consistent with this finding, H&E staining showed evidence of
greater lung tissue inflammation in OVA-challenged Lgals1−/−
mice relative to WT mice (Fig. 7C) and a significantly increased
number of lung tissue eosinophils and T cells based on IHC for
major basic protein (MBP), an eosinophil-specific protein (Fig. 7 D
and E), and CD3, a T cell-specific marker (Fig. 7 F and G),
respectively. Along with increased airway eosinophils, peripheral
blood and BM differential cell counts indicated a significantly
higher percentage of eosinophils in OVA-challenged Lgals1−/−mice
relative to WT counterparts (Fig. 7 H and I).
A larger number of blood vessels in the lungs of WT
OVA-challenged mice exhibited eosinophils (MBP-positive cells)
adherent along the vessel wall relative to lung blood vessels of
Lgals1−/− mice (Fig. 8A, Left). Further, the number of adherent
eosinophils per vessel was also significantly higher in WT OVA-
challenged mice compared with Lgals1−/− counterparts (Fig. 8A,
Right). AHR in control and OVA-challenged WT and Lgals1−/−
mice exposed to increasing concentrations of aerosolized meth-
acholine was evaluated (Fig. 8B). Control mice of both genotypes
displayed only a marginal increase in pulmonary resistance (RL) with
increasing doses of methacholine. In OVA-challenged Lgals1−/−
mice, airway resistance was significantly higher compared with
corresponding control mice even at low doses of methacholine
challenge (i.e., 6 mg/mL), and remained elevated at higher doses.
OVA-challenged WTmice, on the other hand, exhibited increased
airway resistance relative to WT control mice only at higher doses
of methacholine (>25 mg/mL). More importantly, airway resis-
tance in OVA-challenged Lgals1−/− mice was significantly higher
than in WT counterparts at 6, 12, and 25 mg/mL methacholine.
These findings are indicative of a higher tendency to develop
AHR in OVA-challenged Lgals1−/− and are consistent with the
increased cellular inflammation observed in these mice relative to
WT allergen-challenged mice. In addition to cellular inflamma-
tion, airway mucus accumulation and increased airway smooth
muscle mass are important factors that contribute to increased
airway resistance. OVA challenge increased airway mucus secre-
tion and airway smooth muscle mass in WT and Lgals1−/− mice
compared with corresponding control mice (Fig. 8 C–F). Whereas
there was no significant difference between the OVA-challenged
groups with respect to airway mucus secretion (Fig. 8 C and D),
smooth muscle mass in OVA-challenged Lgals1−/−mice was lower
than in WT mice (Fig. 8 E and F).
Modulation of Cytokines and Chemokines in Airways of Allergen-
Challenged WT and Lgals1−/− Mice. Consistent with the asthma
phenotype, IL-5, TNF-α, TGF-β, eotaxin-1, and eotaxin-2 (CCL24)
were all significantly elevated in the BALF of OVA-challenged
mice of both genotypes compared with corresponding control
mice. No significant difference in the levels of any of these
mediators was noted between OVA-challenged Lgals1−/− and
WT mice (Fig. 9A and Fig. S4A). However, TNF-α levels were
significantly higher in lung tissue from OVA-challenged Lgals1−/−
mice than in WT counterparts, and IL-5 and IL-13 also tended to
be higher (Fig. 9B).
Fig. 5. Gal-1–induced apoptosis is mediated by
complex branched N-glycans and involves activation
of the ERK(1/2) signaling pathway. (A) Involvement
of O-glycans in Gal-1–induced apoptosis. Eosinophils
cultured in medium containing BG or vehicle (DMSO)
were treated with rGal-1 (5 μM) and examined for
annexin V positivity. (B) Requirement of complex
branched N-glycans for Gal-1–induced apoptosis. WT
and Mgat5−/− eosinophils were treated with rGal-1
and examined for annexin V positivity. (C) Induction
of ERK(1/2) phosphorylation in Gal-1–treated eosin-
ophils determined by densitometric analysis of
Western blots. (D) Inhibition of ERK(1/2) degradation
by proteasome inhibitor MG132 determined by
densitometric analysis of Western blots. (E) Inhibi-
tion of Gal-1–induced apoptosis by MEK1/2 inhibitor.
(E, Right) Annexin V staining of eosinophils pre-
treated with the indicated inhibitors of signaling
molecules and then with rGal-1 relative to vehicle
alone is shown. (E, Left) Annexin V positivity in vehicle-
treated versus rGal-1–treated cells is shown. (F)
Caspase-independent apoptosis of eosinophils by
Gal-1. Cells were pretreated with caspase inhibitor
(pan; Z-VAD-FMK) at the indicated doses (or vehicle)
followed by rGal-1 or staurosporine and examined for annexin V positivity. (G) Western blot of Gal-1–treated eosinophils with antibodies against cleaved
caspase-3. Data shown in A and B are representative of three experiments and in G of two experiments with eosinophils from different mice. Combined data
(mean ± SEM) of three or four independent experiments in C and D and four to six independent experiments in E and F are shown. *P < 0.05 in C, *P < 0.05 for
50 μM and *P < 0.01 for 100 μM U0126 in E, and *P < 0.01 for 50 and 100 μM Z-VAD in F for comparison with PBS or vehicle-treated cells.
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The increased recruitment of eosinophils to the airways and
peripheral blood of allergen-challenged Lgals1−/− mice relative
to WT mice (Fig. 7) is unlikely to be entirely due to elevated
eotaxin-1 and -2 because levels of these chemokines were not
found to be substantially different between the two allergen-
challenged groups. Thus, we examined inherent differences be-
tween WT and Lgals1−/− eosinophils with respect to migration in
vivo. BM eosinophils from WT and Lgals1−/− mice were car-
boxyfluorescein succinimidyl ester (CFSE)-labeled and infused
into WT mice with thioglycollate (TG)-induced peritoneal in-
flammation. There was a twofold increase in the number of
CFSE-labeled Lgals1−/− eosinophils recruited to the inflamed
peritoneum relative to WT eosinophils based on flow cytometry
analysis of the peritoneal fluid (Fig. 9C and Fig. S4B). This was
reflected in a larger number of total eosinophils (endogenous
eosinophils plus infused eosinophils) in the peritoneum of WT
mice that received Lgals1−/− eosinophils compared with WT
mice that were infused with WT eosinophils (Fig. S4C). We also
compared survival of WT versus Lgals1−/− eosinophils in culture
medium containing low serum up to 24 h but found no inherent
difference in constitutive apoptosis based on annexin V staining
(Fig. S4D), suggesting that endogenous Gal-1 did not regulate
eosinophil viability. Collectively, these findings suggest that Gal-
1–deficient eosinophils exhibit increased ability to recruit to sites
of inflammation compared with WT eosinophils, which could
also contribute to the increased eosinophilia observed in aller-
gen-challenged Lgals1−/− mice.
Discussion
Eosinophils recruited to allergic airways serve as a reservoir for
proinflammatory cytokines, chemokines, growth factors, and
cytotoxic granule proteins (MBP, EPX, and eosinophil cationic
protein) that cause significant epithelial tissue damage and con-
tribute to bronchoconstriction, mucus production, vascular per-
meability, and airway remodeling (19). Given the homeostatic/
antiinflammatory role of Gal-1 in multiple chronic disease
models as well as acute inflammation models (5, 6), we examined
the role played by Gal-1 in allergic airway inflammation and
asthma. Exposure to various allergens (OVA, Alternaria, and
CRA) resulted in increased Gal-1 expression in the lungs due to
the recruitment of Gal-1–expressing inflammatory cells, includ-
ing eosinophils, as well as increased expression of Gal-1 in the
basement membrane of the airway epithelium and extracellular
spaces beneath the epithelium and blood vessel wall. Expression
of Gal-1 has been demonstrated in the nucleus, cytosol, and
intracellular side of cell membranes as well as extracellularly in
culture supernatants and in the ECM of tissues despite the ab-
sence of a secretion signal sequence (5, 20). Based on techniques
used in the current study, soluble Gal-1 was not detectable in the
BALF of OVA-challenged mice. Gal-1 could be secreted at
concentrations below the detection limit of our assay or the se-
creted Gal-1 may rapidly bind to cell-surface glycans or the ECM
and thus not remain in a soluble form at concentrations high
enough to be detected.
Studies with BM-derived eosinophils confirmed that eosino-
phils (nonactivated) express Gal-1 intracellularly but not on the
cell surface. These findings are consistent with Gal-1 expression
in activated T cells where only intracellular expression was noted,
with no detectable cell-surface expression or secretion (15).
Further, intracellular Gal-1 expression or expression on the cell
surface was not induced after stimulation/activation with asthma-
inducing mediators such as TNF-α, eotaxin-1, or SCF-1. Despite
the lack of endogenous cell-surface Gal-1 expression, murine
eosinophils were found to rapidly bind to exogenous/extracellular
Gal-1 on the cell surface in a carbohydrate-dependent manner.
Gal-1 is known to bind preferentially to complex N- and O-glycans
containing terminal modified or unmodified LacNAc resi-
dues (5), and can therefore bind to a host of cell-surface
glycoproteins that contain these glycan components. Glycophenotyp-
ing of murine eosinophils confirmed the expression of complex N- and
O-glycans bearing LacNAc residues on the cell surface that could
potentially bind to Gal-1. Further, lectin inhibition studies dem-
onstrated the involvement of LacNAc residues of eosinophil-
expressed cell-surface glycans in binding to Gal-1. Studies to
determine the relative requirement of N- versus O-glycans for
Gal-1 binding suggest that eosinophil-expressed complex N-gly-
cans are involved in this interaction. Although O-glycans do not
appear to be required for Gal-1 binding, based on increased
binding of exogenous Gal-1 in the absence of complex O-glycans,
it is possible that O-glycans may play a role in regulating Gal-1
Fig. 6. Extracellular Gal-1 differentially regulates
eosinophil adhesion and migration. (A and B) Effect of
rGal-1 at subapoptotic concentrations (<0.25 μM)
on eosinophil adhesion to VCAM-1–coated coverslips
(A) and eotaxin-1–induced migration (B). (C) Inhibi-
tion of ERK activation by Gal-1 at subapoptotic con-
centrations by Western blot analysis. (D) Clustering of
eosinophils, redistribution of CD49d (α4), and colo-
calized expression of rGal-1 with α4-integrin by dual IF
staining with anti-α4 (green) and anti–Gal-1 (red).
(Scale bar, 10 μm.) (E) Effect of rGal-1 at proapoptotic
concentrations on expression of α4 and CCR3 by flow
cytometry. (F and G) Total F-actin and actin cytoskel-
eton in eosinophils treated with rGal-1 at proa-
poptotic concentrations. Combined data (mean ±
SEM) of three experiments in duplicate in A, four ex-
periments in triplicate in B, and three experiments in
C (Left) are shown. Data shown in D–G are represen-
tative of three or four independent experiments with
eosinophils from different mice. *P < 0.05 for 0.1 μM
and *P < 0.01 for 0.25 μM rGal-1–treated cells com-
pared with untreated in A and B.
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binding to N-glycans by masking N-glycans that participate in
binding to Gal-1. This is in contrast to activated T cells, where
both N- and O-glycans participate in Gal-1 binding (14).
Although eosinophils did not appear to secrete Gal-1 in re-
sponse to stimulation with TNF-α, eotaxin-1, or SCF-1 in vitro,
these mediators may play a different role in vivo and induce Gal-1
secretion, which could potentially exert autocrine effects. Fur-
ther, in vivo, eosinophils are likely to be exposed to varying
concentrations of soluble Gal-1 released by other cells such as
endothelial cells (20) or to Gal-1 presented by the ECM (21)
during inflammation. Our in vitro studies demonstrate that Gal-1
rapidly induces apoptosis of eosinophils at high concentrations,
typical of inflammatory reactions. The proapoptotic effect of
Gal-1 has previously been demonstrated in other cell types such
as T cells (14), B cells (22), epithelial cells (23), and endothelial
cells (24) but not macrophages, DCs, or mast cells (25). Gal-1–
induced apoptosis of both BM-derived as well as peripheral
blood eosinophils from allergen-challenged mice occurred at
lower concentrations and more rapidly (≥1 μM by 15 min) than
in T cells (14), B cells (22), and endothelial cells (24). Further,
Gal-1 treatment caused cell shrinkage in eosinophils, a hallmark
feature of apoptosis (26). These Gal-1–mediated effects were
significantly inhibited in the presence of lactose, establishing
their carbohydrate-dependent nature. Gal-1 at higher concen-
trations also caused a marked reduction in total F-actin levels
(indicative of F-actin depolymerization) and disruption of the
cytoskeleton, consistent with cell disintegration into apoptotic
bodies (26). Previous studies investigating the effect of immobilized
Gal-1 (coated on plastic supports) on adhesion and migration
of human eosinophils reported altered actin polymerization/
depolymerization dynamics with a prevalence of glomerular actin
(27), suggesting that the actin cytoskeleton is a target of Gal-1–
mediated signaling. Eosinophils exposed to proapoptotic con-
centrations of Gal-1 exhibited reduced cell-surface expression of
α4 and CCR3. It is possible that these receptors are rapidly
recycled or shed, a phenomenon previously described in other
cell types during apoptosis (28) that may serve as a mechanism to
suppress eosinophil activation and recruitment.
In activated T cells, Gal-1–induced cell death has been shown
to involve the participation of AP-1 (4), NF-κB (29), and Bcl-2
(4) as well as activation of caspases (18), although caspase-
independent T-cell apoptosis has also been shown to occur (30).
In the current study, Gal-1–induced apoptosis of eosinophils did
not appear to involve activation of caspases, similar to the effects
observed in endothelial cells (24). However, a role for ERK(1/2)
was identified. Exposure to rGal-1 at concentrations >1 μΜ
caused a marked increase in phosphorylation of ERK(1/2), and
eosinophil apoptosis was inhibited by the MEK inhibitor U0126.
Whereas activation of the ERK(1/2) pathway is typically known
to govern cell proliferation and differentiation and is protective
against apoptosis (31), recent studies indicate that activation of
ERK by certain stimuli can indeed act as a cell-death signal and
Fig. 8. Increased airway reactivity in allergen-chal-
lenged Gal-1–deficient mice. (A) Quantitation of the
number of lung blood vessels with eosinophils (MBP-
positive cells) and the number of adherent eosino-
phils in the blood vessels of OVA-challenged WT and
Lgals1−/− mice. (B) Pulmonary resistance in saline-
and OVA-challenged WT and Lgals1−/− mice follow-
ing exposure to aerosolized methacholine. (C and D)
Quantitation of mucus secretion (stained pink) in
airways of saline- and OVA-challenged WT and
Lgals1−/− mice along with representative images.
BML, basement membrane length; PAS, periodic
acid–Schiff reagent. (Scale bar, 50 μm.) (E and F)
Quantitation of airway smooth muscle mass based
on α-SMA IHC (stained brown). Representative im-
ages are shown in F. (Scale bar, 50 μm.) Combined
data (mean ± SEM) of mice from two independent
experiments (n = 7–8 mice per group) in A and three independent experiments (n = 7–8 mice for OVA groups and n = 6–7 mice for saline groups) in B, C, and E
are shown. *P < 0.025 in A and *P < 0.05 at 6 and 25 mg/mL and *P < 0.03 at 12 mg/mL methacholine in B for comparison of OVA-challenged groups.
Fig. 7. Gal-1 deficiency leads to increased airway
inflammation after allergen exposure. (A and B)
Number of total cells (A, Left) and eosinophils (A,
Right) and number of PMNs, macrophages (Mac),
and lymphocytes (Lymph) (B) in the BALF from sa-
line- and OVA-challenged WT and Lgals1−/− mice.
(C) Cellular infiltration in lung tissue after H&E
staining. Representative images are shown. (Scale
bar, 50 μm.) (D and E) Quantitation of lung tissue
eosinophils and representative images after MBP IHC
(stained reddish brown). (Scale bar, 50 μm.) (F and G)
Quantitation of lung tissue T cells and representative
images after CD3e IHC (stained brown). (Scale bar,
50 μm.) (H and I) Quantitation of eosinophils in pe-
ripheral blood and BM, respectively, after Hema 3
staining. Combined data (mean ± SEM) of mice from
three independent experiments (n = 8–9 mice for
OVA groups and n = 6 mice for saline groups in A, B,
D, and F; n = 7–8 mice for OVA groups and n = 7
mice for saline groups in H and I) are shown.
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facilitate engagement of apoptotic programs (32). Interestingly,
in the current study, increased ERK(1/2) activation was associ-
ated with a drastic reduction/degradation of ERK(1/2) by the
proteasome. Previous studies have demonstrated that, in addi-
tion to functioning as an upstream activator of ERK(1/2), MEKK1
has E3 ubiquitin ligase activity and can thus mediate ubiquitina-
tion and degradation of ERK(1/2), which may serve as a negative
regulatory mechanism for decreasing ERK(1/2) activity in stress-
induced cells (33).
Apart from its ability to induce apoptosis, Gal-1 has been
shown to affect immune cell motility. Whereas PMNs were less
migratory toward IL-8 after treatment with Gal-1 (34), DCs
demonstrated increased chemokine-induced migration (35) in
vitro. Further, at lower concentrations (subapoptotic), Gal-1 has
been shown to inhibit T-cell adhesion to ECM proteins in a dose-
dependent manner (36). Our studies show that Gal-1 treatment
at subapoptotic concentrations (up to 0.25 μM) causes eosino-
phils to form clusters, increases their adhesion to VCAM-1, and
alters distribution of α4-integrin to the cell periphery but does
not affect the expression level of adhesion receptors (α4- or
β2-integrins and L-selectin). In this regard, Gal-1 has been reported
to directly bind to β1-integrins on vascular smooth muscle cells,
transiently increasing the availability of its active form on the cell
surface and thus modulating adhesion (37). Treatment of eo-
sinophils with Gal-1 at the same concentrations that increased
adhesion resulted in decreased eotaxin-1–induced migration,
with the expression level of CCR3 remaining unaltered. Exogenous
Gal-1–induced clustering of cells along with increased adhesion to
VCAM-1 and inhibition of ERK(1/2) activation [a signaling
molecule required for eotaxin-1–induced eosinophil migration
(38)] may result in the cells being less motile to undergo directed
movement toward eotaxin-1. These in vitro findings are further
supported by observations in our model of allergic airway in-
flammation where eosinophils adherent in lung blood vessels
were more commonly noted in allergen-challenged WT mice
than in Lgals1−/− mice, potentially due to exposure to Gal-1 se-
creted by or presented on the surface of endothelial cells. Indeed,
endothelial cells in allergen-challenged mice express Gal-1 based
on our IHC data. Additionally, allergen-challenged Lgals1−/−mice
exhibited increased lung tissue eosinophils relative to WT coun-
terparts despite similar levels of the eosinophil-specific chemokines
eotaxin-1 and -2, which could be due to the lack of the inhibitory/
limiting effects of Gal-1 on eosinophil migration that was noted
in vitro.
Consistent with the inhibitory effect of exogenous Gal-1 on
eosinophil migration in vitro and the increased number of blood
vessels with adherent eosinophils in allergen-challenged WT
mice relative to Gal-1–deficient mice, eosinophil recruitment in
the BALF and lung tissue after allergen challenge was significantly
lower in WT mice than in Gal-1–deficient counterparts. Further,
these mice had lower peripheral blood and BM eosinophilia. In a
WT setting, depending on concentrations in the local milieu, ex-
tracellular Gal-1 may regulate eosinophilia by inducing apoptosis
of differentiated eosinophils in the BM or inhibit their migration/
mobilization from the BM to sites of inflammation. Indeed,
previous studies have shown that administration of Gal-1 can
prevent cyclophosphamide- and G-CSF–induced migration of
progenitor cells from the BM in vivo (39). Along with the in-
creased eosinophilia, allergen-challenged Gal-1–deficient mice
exhibited significantly elevated T cells and AHR. However, airway
smooth muscle mass was somewhat lower in allergen-challenged
Gal-1–deficient mice despite more inflammation. Gal-1 is secreted
by vascular smooth muscle cells and is known to induce vascular
smooth muscle proliferation, attachment, spreading, and migra-
tion (37). It is conceivable that it may have a similar effect on
airway smooth muscle cells, which might explain the decrease in
α-smooth muscle actin (α-SMA)–positive cells in allergen-chal-
lenged Gal-1–deficient mice relative to WT counterparts. Finally,
TNF-α in the lung tissue of allergen-challenged Gal-1–deficient
mice was significantly higher relative to WT counterparts. TNF-α
is secreted by eosinophils and T cells, both of which are elevated in
allergen-challenged Gal-1–deficient mice. It is known to promote
migration of inflammatory cells as well as induction of AHR (40)
and inhibit the suppressive function of both naturally occurring
and induced Tregs in asthmatic patients (41). In this regard,
studies have shown that Gal-1 is required for the regulatory
activity of CD4+CD25+ Tregs (10). The inherently increased
ability of Gal-1–deficient eosinophils to recruit to sites of in-
flammation versus WT cells as noted in the peritonitis model,
suggestive of a role for intracellular Gal-1 in regulating eosinophil
migration independent of the extracellular effect of Gal-1, could
also be an important player responsible for the increased eosin-
ophilia in allergen-challenged Gal-1–deficient mice. In a recent
study, administration of rGal-1 to mice with IgE-mediated allergic
conjunctivitis resolved clinical signs as well as reduction in Th2
cytokines, eotaxin, RANTES, and MAPK signaling. However, this
was associated with increased Gal-1 expression and eosinophilia in
the conjunctiva relative to untreated mice (42).
Overall, our studies demonstrate that Gal-1, which is induced
in the lung in response to allergen challenge, is important in
regulating airway inflammation. This is supported by our in vitro
findings that extracellular Gal-1 can bind to eosinophil-expressed
cell-surface glycans in a carbohydrate-dependent manner to in-
hibit cell migration and induce apoptosis as well as our in vivo
studies demonstrating increased eosinophilia and airway inflam-
mation in the absence of the endogenous lectin. Targeting eosino-
phils is an important strategy for alleviating not only allergic asthma
but potentially even other eosinophil-driven disorders.
Materials and Methods
Mice. Mice with a deletion of the gene encoding Gal-1 (Lgals1−/−), originally
provided by F. Poirier, Institut Jacques Monod, Paris, France, or Mgat5
(Mgat5−/−; obtained from the Consortium for Functional Glycomics) (43),
both on C57BL/6 background, were bred in-house. Age- and gender-matched
C57BL/6 mice (8–12 wk old) were used as WT controls. All studies involving
Fig. 9. Inflammatory cytokines and chemokines in airways of allergen-
challenged WT and Gal-1–deficient mice. (A) Eotaxin-1 and -2 (Eot-1, Eot-2)
levels in the BALF of saline- and OVA-challenged WT and Lgals1−/− mice.
(B) IL-5, TNF-α, and IL-13 levels in lung lysates from the above groups of mice.
Combined data (mean ± SEM) of mice from three independent experiments
(n = 7–9 mice for OVA groups and n = 6–7 mice for saline groups) are shown
in A and B. (C) Recruitment of i.v. infused CFSE-labeled BM eosinophils from
WT or Lgals1−/− mice to the peritoneum of mice with TG-induced in-
flammation. Combined data (mean ± SD) of two out of three experiments in
duplicate mice with similar results are shown.
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mice were performed following standards and procedures approved by the
Institutional Animal Care and Use Committee at the University of Minnesota.
Culture of Murine Eosinophils and Preparation of Recombinant Gal-1. Eosino-
phils were cultured from naïve BM of WT, Lgals1−/−, and Mgat5−/− mice as
described previously (43, 44). Expression and purification of recombinant
Gal-1 were accomplished as outlined previously (45). LPS was removed by
Detoxi-Gel endotoxin removing gel (Pierce), and samples were tested for LPS
content using the gel-clot Limulus test (<0.5 IU/mg).
Cell Lysis and Western Blot Analysis. Detailed methods for cell lysis and
Western blotting are described in SI Materials and Methods.
Gal-1 Expression and Binding to Eosinophils. Expression of Gal-1 by murine
eosinophils was evaluated by flow cytometry and confocal microscopy after IF
staining as detailed in SI Materials and Methods using polyclonal antibodies
against human Gal-1 prepared as described previously (46).
To determine whether Gal-1 binds to eosinophils, cells were treated with
rGal-1 at 0.1 or 0.25 μΜ in PBS or vehicle alone for 15 min at 37 °C. After washing
(once with PBS), Gal-1 expression on the cell surface (nonpermeabilized) was
examined by flow cytometry using antibodies against Gal-1 (SI Materials and
Methods). In some experiments, cells were incubated with rGal-1 in the
presence of lactose (10 or 30 mM), a Gal-1–specific disaccharide, or maltose
as a control before analysis.
Glycophenotyping and Gal-1–Binding Partners Expressed in Eosinophils. Bio-
tinylated plant lectins with known specificities were used to identify glycan
epitopes on the cell surface of BM-derived eosinophils. Cells were incubated
with TL, MAL-II, SNA, PHA-L, or PNA (all at 20 μg/mL; Vector Laboratories) or
vehicle (PBS) for 30 min followed by DyLight 488 conjugated to streptavidin
(Vector Laboratories). In some studies, eosinophils were preincubated with
the above lectins or vehicle alone for 20 min at room temperature and then
treated with rGal-1 (0.1 μM). Gal-1 binding to the cell surface was examined
by flow cytometry as described earlier. Results were expressed as fold change
in geometric mean fluorescence intensity relative to vehicle-treated cells.
To examine the requirement of O-glycans, eosinophils were cultured in
medium containing BG (2 mM) or vehicle (DMSO) for 65 h as described (14)
and then examined for rGal-1 binding by flow cytometry. To examine the
requirement of complex branched N-glycans, binding of rGal-1 to BM eo-
sinophils from Mgat5−/− mice relative to WT mice was evaluated.
Apoptosis Assays. Eosinophils were treated with 0.1–5 μM rGal-1 in PBS (or
PBS only) at 37 °C for up to 60 min and examined for cell viability by trypan
blue exclusion. In another set of experiments, eosinophils were treated with
rGal-1, washed, and analyzed by flow cytometry using the Annexin V-FITC
Apoptosis Detection Kit (eBioscience). Briefly, eosinophils were collected
after treatment with Gal-1, resuspended in binding buffer, and stained with
FITC-conjugated annexin V for 15 min followed by propidium iodide (PI). To
additionally examine the effect of Gal-1 on peripheral blood eosinophils,
total leukocytes (after lysis of red blood cells) obtained from allergen-chal-
lenged mice were exposed to PBS or rGal-1 (1 μM for 15 min at 37 °C). Cells
were dual-stained with annexin V-FITC and phycoerythrin (PE)-conjugated
rat anti-mouse Siglec-F (BD Biosciences). PE-conjugated rat IgG was used as
isotype control. Changes in annexin V positivity in the Siglec-F–positive
population (eosinophils) were determined by flow cytometry. Involvement
of O- versus complex N-glycans in Gal-1–mediated apoptosis was examined
by exposing eosinophils cultured in medium containing BG or BM eosino-
phils from Mgat5−/− mice to rGal-1 (5 μM) and analyzed for annexin V
staining. To examine the role of specific signaling molecules in Gal-1–
mediated eosinophil apoptosis, cells were incubated with Y-27632 (inhibitor
of ROCK1; Cayman Chemical), U0126 (inhibitor of MEK; Cayman Chemical),
LY294002 (inhibitor of PI3K; Sigma-Aldrich), Bay 61-3606 (synonym Syk in-
hibitor IV, inhibitor of Syk tyrosine kinase; EMD Millipore), or pan-caspase
inhibitor [synonym Z-VAD (OMe)-FMK; Santa Cruz Biotechnology] at 10, 50,
or 100 μΜ for 20 min in DMEM at 37 °C and then exposed to rGal-1 (1–5 μM)
or PBS alone as described above. Cells treated with staurosporine (20 μM;
Santa Cruz Biotechnology), a known inducer of caspase-mediated apoptosis
(47), served as a positive control. Cells preincubated with DMSO (Sigma-
Aldrich) or water alone in media served as the vehicle control. Additionally,
cells treated with rGal-1 or staurosporine (20 μΜ) for 60 min were applied to
poly-L-lysine–coated slides and evaluated by TUNEL assay (DeadEnd Colori-
metric TUNEL System; Promega).
Adhesion and Migration Assays. The effects of Gal-1 on eosinophil adhesion
and migration were evaluated as described previously (48, 49) and are de-
tailed in SI Materials and Methods.
Cell-Surface Receptor Expression and Actin Polymerization. Changes in the
expression of cell-surface adhesion molecules and the actin cytoskeleton
(based on phalloidin binding) after treatment with rGal-1 were examined
by flow cytometry and confocal microscopy as detailed in SI Materials
and Methods.
Evaluation of Gal-1–α4-Integrin Interaction. BM eosinophils were treated with
rGal-1 (0.25 μM) in the presence or absence of 30 mM lactose (or maltose) or
with buffer alone in suspension and then cytocentrifuged (75 × g) onto glass
slides. Cells were dual-stained with anti–Gal-1 polyclonal antibodies (30 μg/mL)
and anti-CD49d mAb (clone R1-2, 10 μg/mL; BD Biosciences) followed by
Rhodamine Red-X–conjugated goat anti-rabbit IgG and FITC-conjugated goat
anti-rat IgG, respectively (both from Jackson ImmunoResearch Laborato-
ries), and examined by confocal microscopy. Rabbit IgG (for Gal-1) and rat
IgG (for CD49d) were used as negative controls. In some studies, α4-
transfected CHO-K1, kindly provided by Yoshikazu Takada, Scripps Re-
search Institute, La Jolla, CA (50), or nontransfected control CHO-K1 cells
cultured to 70% confluence were treated with PBS or rGal-1 and examined
for Gal-1 binding by flow cytometry with antibodies against Gal-1 (see SI
Materials and Methods for details).
Models of Allergic Airway Inflammation. For acute allergen-induced airway
inflammation, WT or Lgals1−/− mice (C57BL/6; 8–12 wk old) were sensitized
and challenged with OVA (grade V; Sigma-Aldrich) as described (51). Control
mice were administered saline instead of OVA for sensitization and chal-
lenge. Additionally, lungs from C57BL/6 WT mice exposed to chronic chal-
lenge with OVA (52), acute challenge with CRA (Hollister-Stier Laboratories)
(48), or an extract of A. alternata (Greer) (53) were harvested. Mice were
killed 24 h after the last allergen challenge in all models.
Measurement of Airway Responsiveness. Pulmonary function in control and
acute OVA-challenged WT and Lgals1−/− mice was assessed by invasive
plethysmography (FinePointe RC System; Buxco) (51). Changes in pulmonary
resistance were monitored continuously in response to saline followed by
increasing concentrations of inhaled methacholine (3–50 mg/mL) nebulized
for 18–20 s and expressed as mean RL values following each dose of
methacholine.
Sample Collection and Analysis. Total cell counts in the BALF were determined
using a hemocytometer. Differential cell counts in the BALF as well as blood
and BM were determined based on morphologic and histologic criteria after
staining cytocentrifuged samples with the Hema 3 System (Thermo Fisher
Scientific). BALF supernatants were stored at−80 °C for later analysis. Right lungs
were snap-frozen and left lungs were perfused and fixed in 4% (vol/vol) para-
formaldehyde before paraffin embedding. Lgals1 expression in lung tissue was
examined by quantitative PCR as described in SI Materials and Methods.
Lung Histology. Paraffin-embedded tissue sections from OVA-challenged WT
and Lgals1−/− mice were evaluated for cellular infiltration [total cells, eo-
sinophils (MBP-positive), and lymphocytes (CD3-positive)], Gal-1 expression,
smooth muscle hyperplasia, and airway mucus secretion by histology as de-
scribed in SI Materials and Methods. To examine Gal-1 expression by lung tissue
eosinophils, sections were dual-stained with antibodies against Gal-1 (4 μg/mL)
and mAb against EPX (10 μg/mL) (54) and examined by confocal microscopy.
Measurement of Lung Cytokines and Chemokines. Th1 (IL-2, IFN-γ)/Th2 (IL-4,
IL-5, IL-13) cytokine and TNF-α levels in supernatants of lung tissue lysates
and/or BALF were determined by flow cytometry using CBA Flex Set Kits (BD
Biosciences) and expressed as pg cytokine per 100 mg lung tissue protein or
pg/mL BALF. Eotaxin-1, eotaxin-2, and TGF-β1 in the BALF were measured
using ELISA kits (R&D Systems).
In Vivo Migration Assay. Migration/recruitment of infused CFSE-labeled
BM-derived eosinophils from WT versus Lgals1−/− mice was evaluated in a
model of TG-induced peritoneal inflammation (43). Total and differential
cell counts in the peritoneal fluid were determined and cells were analyzed
by flow cytometry to determine the number of CFSE-labeled eosinophils.
Statistical Analysis. Results are expressed as mean ± SEM (or mean ± SD
where noted) of combined data from multiple experiments. Statistical
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comparison between two groups was determined by an unpaired Student’s t
test. Comparisons between control and multiple treatment conditions were
carried out by ANOVA followed by Dunnett’s posttest. A P value < 0.05 was
considered to be significant.
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